Table 2.
Treatment Characteristics.
| Treatment Characteristics | Univariable Analysis | |||||
|---|---|---|---|---|---|---|
| OS | PFS | |||||
| Parameter | Categories | Number (%), n = 46 (100%) | HR (95% CI) | p-Value | HR (95%CI) | p-Value |
| Enucleation | No | 22 (47.8) | ||||
| Yes | 24 (52.2) | |||||
| Plaque RT | No | 20 (43.5) | ||||
| Yes | 26 (56.5) | |||||
| Lines of Prior Therapy | 0 | 43 (93.5) | 1.3 (0.8, 2.3) | 0.30 | 1.0 (0.6, 1.8) | 0.89 |
| 1 | 2 (4.3) | |||||
| > 1 | 1 (2.2) | |||||
| Immunotherapy | Single ICI | 35 (76.1) | 2.5 (0.9, 6.6) | 0.053 | 2.0 (0.9, 4.1) | 0.076 |
| Combination ICI | 11 (23.9) | 0.4 (0.2, 1.0) | 0.053 | 0.5 (0.2, 1.1) | 0.076 | |
| Cycles of ICI Completed | Median (IQR) | 10 (8) | 0.9 (0.9, 1.0) | 0.009 | 0.9 (0.9, 1.0) | 0.003 |
| Reason for Discontinuation | Progression/Death | 31 (67.4) | ||||
| Toxicity | 11 (23.9) | |||||
| Other | 4 (8.7) | |||||
| IRAE Grade | None | 24 (52.2) | ||||
| Grade 1 | 7 (15.2) | |||||
| Grade 2 | 9 (19.6) | |||||
| Grade 3 | 6 (13.0) | |||||
| Grade 4 | 0 (0) | |||||
| Liver Directed Therapy | None | 23 (50.0) | 0.9 (0.5, 1.8) | 0.8 | 1.0 (0.5, 1.7) | 0.88 |
| Surgical Resection | 2 (4.3) | |||||
| SBRT/RT | 9 (19.6) | |||||
| TACE | 6 (13.0) | |||||
| Radioembolization | 1 (2.2) | |||||
| Multiple | 5 (10.9) | |||||
| Objective Response Rate | CR | 1 (2.2) | ||||
| PR | 1 (2.2) | |||||
| SD | 8 (17.4) | |||||
| PD | 34 (73.9) | |||||
| Unable to Assess | 2 (4.3) | |||||
IRAE, Immune-related adverse event.